Global Flu Vaccines Market Key Players Competitive Survey Report 2024
Report Code: KNJ1771970 No. of Pages: 125 Category: Medical Devices
Publisher: Date of Publish:
Publisher: Date of Publish:
The global Flu Vaccines market size in 2023 is 8164.8 million US dollars, and it is expected to be 14830.0 million US dollars by 2030, with a compound annual growth rate of 8.90% expected in 2024-2030. MARKET COMPETITIVE LANDSCAPE: The main players in the Flu Vaccines market include AstraZeneca (U.K.), BioDiem (Canada), Novasep (France), MerckKGaA (Germany), and Charles River Laboratories (U.K.). The share of the top 3 players in the Flu Vaccines market is XX%. REGION SHARE: The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Flu Vaccines market, and Asia Pacific accounted for XX%. SEGMENT OVERVIEW: The report segments the market by Type and Application. Quadrivalent Influenza Vaccines accounted for XX% of Flu Vaccines market in 2023. Trivalent Influenza Vaccines share of XX%. Hospitals and Clinics accounted for XX% of the Flu Vaccines market in 2023. Research Organizations and Academic Institutes accounts for XX%. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. COVID-19 Impact: Outbreak of COVID-19 pandemic due to lockdown restrictions imposed by governments around the world has affected the growth of the global Flu Vaccines market in 2020. The containment measures taken by the governments of various countries in response to control the outbreak of COVID-19 disrupted the entire supply chain by creating logistical interruptions, transportation restrictions, and product supply across borders. The report analyzes the key trends in each segment of the global Flu Vaccines market along with global and country-level forecasts from 2024 to 2028. Our report segments the market based on types and applications, thereby providing a detailed analysis of the market to help gain an in-depth understanding of the market and enable market participants, stakeholders, investors, etc. to have a clearer understanding of the market and judgment. Key benefits to stakeholders: The report provides a comprehensive quantitative analysis of various segments, historical and current market trends, market forecasts, and dynamics of the Flu Vaccines market for 2017-2028. The research report provides the latest information on the market drivers, challenges and opportunities of the global Flu Vaccines market. The study profiles the leading as well as the fastest growing regional markets. It further enables stakeholders to identify key country-level markets within each region. Porter's Five Forces Analysis helps stakeholders assess the impact of new entrants, competitors, supplier strength, buyer strength, and threat of substitution. It helps stakeholders analyze the level of competition in the Flu Vaccines industry and its attractiveness. The competitive landscape enables stakeholders to understand their competitive environment and gain insight into the current position of the key players in the market. Highlights-Regions North America United States Canada Europe Germany France UK Italy Russia Spain Nordic Asia Pacific China Japan South Korea India Southeast Asia Australia Latin America Brazil Mexico Argentina Middle East & Africa Egypt South Africa UAE Turkey Saudi Arabia Player list AstraZeneca (U.K.) BioDiem (Canada) Novasep (France) MerckKGaA (Germany) Charles River Laboratories (U.K.) uniQure N.V. (Netherlands) Waisman Biomanufacturing (U.S.) Creative-Biogene (U.S.) Aldevron (U.S.) Oxford Biomedica (U.K.) Thermo Fisher Scientific Inc (U.S.) Fujifilm Corporation (Japan) Spark Therapeutics Inc. (U.S.) ABL Inc. (U.S.) Boehringer Ingelheim International GmbH. (Germany) Brammer Bio (U.S.) Pfizer Inc. (U.S.) Types list Quadrivalent Influenza Vaccines Trivalent Influenza Vaccines Whole Virus Vaccines Split Virus Vaccines Subunit Vaccines Live Attenuated Virus Vaccines Application list Hospitals and Clinics Research Organizations and Academic Institutes Others
Table of Content 1 Flu Vaccines Market Introduction and Overview 1.1 Flu Vaccines Definition 1.2 Research Purposes 1.3 Report Timeline 1.4 Economic Analysis of Global Regions 1.5 Inflation Analysis 1.6 The Impact of the Russian-Ukrainian War on the Market 1.7 Coronavirus Disease 2020 (COVID-19) Impact on Global 2 Global Flu Vaccines Historical Market Analysis by Type 2.1 Market Size Analysis by Types 2.2 Global Flu Vaccines Revenue and Market Share by Type 2.3 Global Flu Vaccines Sales and Market Share by Type 3 Global Flu Vaccines Historical Market Analysis by Application 3.1 Market Size Analysis by Application 3.2 Global Flu Vaccines Revenue Market Share by Application (2019-2024) 3.3 Global Flu Vaccines Sales Market Share by Application (2019-2024) 4 Global Market Growth Trends Analysis 4.1 Global Flu Vaccines Market Size (2019-2024) 4.2 Flu Vaccines Growth Trends Analysis by Regions 4.2.1 Flu Vaccines Market Size by Regions: 2019 VS 2024 VS 2030 4.2.2 Flu Vaccines Historic Revenue Market Size by Regions (2019-2024) 4.2.3 Flu Vaccines Historic Sales Market Size by Regions (2019-2024) 4.2.4 North America Flu Vaccines Market Size (2019-2024) 4.2.5 Europe Flu Vaccines Market Size (2019-2024) 4.2.6 Asia-Pacific Flu Vaccines Market Size (2019-2024) 4.2.7 Latin America Flu Vaccines Market Size (2019-2024) 4.2.8 Middle East & Africa Flu Vaccines Market Size (2019-2024) 5 North America 5.1 North America Flu Vaccines Revenue by Countries 5.1.1 North America Flu Vaccines Revenue by Countries (2019-2024) 5.1.2 North America Flu Vaccines Sales by Countries (2019-2024) 5.2 North America Flu Vaccines Sales by Types 5.3 North America Flu Vaccines Sales by Applications 5.4 United States 5.5 Canada 6 Asia Pacific 6.1 Asia Pacific Flu Vaccines Revenue by Countries 6.1.1 Asia Pacific Flu Vaccines Revenue by Countries (2019-2024) 6.1.2 Asia Pacific Flu Vaccines Sales by Countries (2019-2024) 6.2 Asia Pacific Flu Vaccines Sales by Types 6.3 Asia Pacific Flu Vaccines Sales by Applications 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Flu Vaccines Revenue by Countries 7.1.1 Europe Flu Vaccines Revenue by Countries (2019-2024) 7.1.2 Europe Flu Vaccines Sales by Countries (2019-2024) 7.2 Europe Flu Vaccines Sales by Types 7.3 Europe Flu Vaccines Sales by Applications 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 7.9 Spain 7.10 Nordic 8 Latin America 8.1 Latin America Flu Vaccines Revenue by Countries 8.1.1 Latin America Flu Vaccines Revenue by Countries (2019-2024) 8.1.2 Latin America Flu Vaccines Sales by Countries (2019-2024) 8.2 Latin America Flu Vaccines Sales by Types 8.3 Latin America Flu Vaccines Sales by Applications 8.4 Brazil 8.5 Argentina 8.6 Mexico 9 Middle East & Africa 9.1 Middle East & Africa Flu Vaccines Revenue by Countries 9.1.1 Middle East & Africa Flu Vaccines Revenue by Countries (2019-2024) 9.1.2 Middle East & Africa Flu Vaccines Sales by Countries (2019-2024) 9.2 Middle East & Africa Flu Vaccines Sales by Types 9.3 Middle East & Africa Flu Vaccines Sales by Applications 9.4 Egypt 9.5 South Africa 9.6 UAE 9.7 Turkey 9.8 Saudi Arabia 10 Global Flu Vaccines Market Competition, by Players 10.1 Global Flu Vaccines Revenue and Market Share by Players 10.2 Market Concentration Rate 10.2.1 Top 3 Flu Vaccines Players Market Share in 2023 10.2.2 Top 6 Flu Vaccines Players Market Share in 2023 10.2.3 Market Competition Trend 10.3 Flu Vaccines Players Head Office, Business Provided 10.4 Flu Vaccines Mergers & Acquisitions 10.5 Flu Vaccines New Entrants and Expansion Plans 11 Players Profiles 11.1 AstraZeneca (U.K.) 11.1.1 AstraZeneca (U.K.) Company Profile 11.1.2 Flu Vaccines Product Overview 11.1.3 AstraZeneca (U.K.) Flu Vaccines Market Performance (2019-2024) 11.1.4 AstraZeneca (U.K.) Business Overview 11.1.5 Recent Developments and Plans 11.2 BioDiem (Canada) 11.2.1 BioDiem (Canada) Company Profile 11.2.2 Flu Vaccines Product Overview 11.2.3 BioDiem (Canada) Flu Vaccines Market Performance (2019-2024) 11.2.4 BioDiem (Canada) Business Overview 11.2.5 Recent Developments and Plans 11.3 Novasep (France) 11.3.1 Novasep (France) Company Profile 11.3.2 Flu Vaccines Product Overview 11.3.3 Novasep (France) Flu Vaccines Market Performance (2019-2024) 11.3.4 Novasep (France) Business Overview 11.3.5 Recent Developments and Plans 11.4 MerckKGaA (Germany) 11.4.1 MerckKGaA (Germany) Company Profile 11.4.2 Flu Vaccines Product Overview 11.4.3 MerckKGaA (Germany) Flu Vaccines Market Performance (2019-2024) 11.4.4 MerckKGaA (Germany) Business Overview 11.4.5 Recent Developments and Plans 11.5 Charles River Laboratories (U.K.) 11.5.1 Charles River Laboratories (U.K.) Company Profile 11.5.2 Flu Vaccines Product Overview 11.5.3 Charles River Laboratories (U.K.) Flu Vaccines Market Performance (2019-2024) 11.5.4 Charles River Laboratories (U.K.) Business Overview 11.5.5 Recent Developments and Plans 11.6 uniQure N.V. (Netherlands) 11.6.1 uniQure N.V. (Netherlands) Company Profile 11.6.2 Flu Vaccines Product Overview 11.6.3 uniQure N.V. (Netherlands) Flu Vaccines Market Performance (2019-2024) 11.6.4 uniQure N.V. (Netherlands) Business Overview 11.6.5 Recent Developments and Plans 11.7 Waisman Biomanufacturing (U.S.) 11.7.1 Waisman Biomanufacturing (U.S.) Company Profile 11.7.2 Flu Vaccines Product Overview 11.7.3 Waisman Biomanufacturing (U.S.) Flu Vaccines Market Performance (2019-2024) 11.7.4 Waisman Biomanufacturing (U.S.) Business Overview 11.7.5 Recent Developments and Plans 11.8 Creative-Biogene (U.S.) 11.8.1 Creative-Biogene (U.S.) Company Profile 11.8.2 Flu Vaccines Product Overview 11.8.3 Creative-Biogene (U.S.) Flu Vaccines Market Performance (2019-2024) 11.8.4 Creative-Biogene (U.S.) Business Overview 11.8.5 Recent Developments and Plans 11.9 Aldevron (U.S.) 11.9.1 Aldevron (U.S.) Company Profile 11.9.2 Flu Vaccines Product Overview 11.9.3 Aldevron (U.S.) Flu Vaccines Market Performance (2019-2024) 11.9.4 Aldevron (U.S.) Business Overview 11.9.5 Recent Developments and Plans 11.10 Oxford Biomedica (U.K.) 11.10.1 Oxford Biomedica (U.K.) Company Profile 11.10.2 Flu Vaccines Product Overview 11.10.3 Oxford Biomedica (U.K.) Flu Vaccines Market Performance (2019-2024) 11.10.4 Oxford Biomedica (U.K.) Business Overview 11.10.5 Recent Developments and Plans 11.11 Thermo Fisher Scientific Inc (U.S.) 11.11.1 Thermo Fisher Scientific Inc (U.S.) Company Profile 11.11.2 Flu Vaccines Product Overview 11.11.3 Thermo Fisher Scientific Inc (U.S.) Flu Vaccines Market Performance (2019-2024) 11.11.4 Thermo Fisher Scientific Inc (U.S.) Business Overview 11.11.5 Recent Developments and Plans 11.12 Fujifilm Corporation (Japan) 11.12.1 Fujifilm Corporation (Japan) Company Profile 11.12.2 Flu Vaccines Product Overview 11.12.3 Fujifilm Corporation (Japan) Flu Vaccines Market Performance (2019-2024) 11.12.4 Fujifilm Corporation (Japan) Business Overview 11.12.5 Recent Developments and Plans 11.13 Spark Therapeutics Inc. (U.S.) 11.13.1 Spark Therapeutics Inc. (U.S.) Company Profile 11.13.2 Flu Vaccines Product Overview 11.13.3 Spark Therapeutics Inc. (U.S.) Flu Vaccines Market Performance (2019-2024) 11.13.4 Spark Therapeutics Inc. (U.S.) Business Overview 11.13.5 Recent Developments and Plans 11.14 ABL Inc. (U.S.) 11.14.1 ABL Inc. (U.S.) Company Profile 11.14.2 Flu Vaccines Product Overview 11.14.3 ABL Inc. (U.S.) Flu Vaccines Market Performance (2019-2024) 11.14.4 ABL Inc. (U.S.) Business Overview 11.14.5 Recent Developments and Plans 11.15 Boehringer Ingelheim International GmbH. (Germany) 11.15.1 Boehringer Ingelheim International GmbH. (Germany) Company Profile 11.15.2 Flu Vaccines Product Overview 11.15.3 Boehringer Ingelheim International GmbH. (Germany) Flu Vaccines Market Performance (2019-2024) 11.15.4 Boehringer Ingelheim International GmbH. (Germany) Business Overview 11.15.5 Recent Developments and Plans 11.16 Brammer Bio (U.S.) 11.16.1 Brammer Bio (U.S.) Company Profile 11.16.2 Flu Vaccines Product Overview 11.16.3 Brammer Bio (U.S.) Flu Vaccines Market Performance (2019-2024) 11.16.4 Brammer Bio (U.S.) Business Overview 11.16.5 Recent Developments and Plans 11.17 Pfizer Inc. (U.S.) 11.17.1 Pfizer Inc. (U.S.) Company Profile 11.17.2 Flu Vaccines Product Overview 11.17.3 Pfizer Inc. (U.S.) Flu Vaccines Market Performance (2019-2024) 11.17.4 Pfizer Inc. (U.S.) Business Overview 11.17.5 Recent Developments and Plans 12 Global Flu Vaccines Forecast Market Analysis by Type 12.1 Global Flu Vaccines Revenue Market Forecast by Type (2024-2030) 12.2 Global Flu Vaccines Sales Market Forecast by Type (2024-2030) 13 Global Flu Vaccines Forecast Market Analysis by Application 13.1 Flu Vaccines Revenue Market Forecast by Application (2024-2030) 13.2 Flu Vaccines Sales Market Forecast by Application (2024-2030) 14 Global Market Growth Forecast Analysis 14.1 Global Flu Vaccines Forecast Market Size (2024-2030) 14.2 Flu Vaccines Growth Trends Forecast Analysis by Regions 14.2.1 Flu Vaccines Revenue Forecast Market Size by Regions (2024-2030) 14.2.2 Flu Vaccines Sales Forecast Market Size by Regions (2024-2030) 14.2.3 North America Flu Vaccines Forecast Market Size (2024-2030) 14.2.4 Europe Flu Vaccines Forecast Market Size (2024-2030) 14.2.5 Asia-Pacific Flu Vaccines Forecast Market Size (2024-2030) 14.2.6 Latin America Flu Vaccines Forecast Market Size (2024-2030) 14.2.7 Middle East & Africa Flu Vaccines Forecast Market Size (2024-2030) 15 Flu Vaccines Manufacturing Cost Analysis 15.1 Flu Vaccines Key Raw Materials Analysis 15.1.1 Key Raw Materials 15.1.2 Price Trend of Key Raw Materials 15.1.3 Key Suppliers of Raw Materials 15.2 Proportion of Manufacturing Cost Structure 15.2.1 Raw Materials 15.2.2 Labor Cost 15.2.3 Manufacturing Expenses 15.3 Manufacturing Process Analysis of Flu Vaccines 15.4 Flu Vaccines Industrial Chain Analysis 16 Market Channel, Distributors, Traders and Dealers 16.1 Market Channel Status 16.1.1 Direct Marketing 16.1.2 Indirect Marketing 16.2 Flu Vaccines Typical Distributors 16.3 Flu Vaccines Typical Customers 17 Flu Vaccines Industry Dynamic Analysis 17.1 Flu Vaccines Market Trends Analysis 17.2 Flu Vaccines Market Drivers Analysis 17.3 Flu Vaccines Market Challenges Analysis 17.4 Flu Vaccines Market Restraints Analysis 18 Research Findings and Conclusion
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com